CRISPR Therapeutics AG (CRSP)
Healthcare • Biotechnology
StockNasdaqGMSwitzerlandCH0334081137
42.62 USD
-6.84% today Updated 13 Nov 2026 10:44
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by CRISPR Therapeutics AG, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 10:44. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
11 Feb 2027
in 90 days · 16:00 · estimate -1.18
Last results
-1.15 vs -1.06 estimated
02 Nov 2026 · Miss -8.5%
Beat the estimate
7 of 12
5 missed · 0 in line
Average surprise
+191.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | -1.18 | — | — | Upcoming |
| 02 Nov 2026 16:00 | -1.06 | -1.15 | -8.5% | Miss |
| 03 Aug 2026 16:00 | -1.18 | -0.94 | +20.6% | Beat |
| 04 May 2026 16:00 | -1.23 | -1.28 | -3.7% | Miss |
| 12 Feb 2026 16:00 | -1.23 | -1.37 | -11.7% | Miss |
| 10 Nov 2025 08:00 | -1.29 | -1.17 | +9.2% | Beat |
| 04 Aug 2025 16:00 | -1.40 | -1.29 | +7.8% | Beat |
| 06 May 2025 16:00 | -1.28 | -1.58 | -23.8% | Miss |
| 11 Feb 2025 16:00 | -1.19 | -0.44 | +62.9% | Beat |
| 05 Nov 2024 09:00 | -1.40 | -1.01 | +28.1% | Beat |
| 05 Aug 2024 16:00 | -1.43 | -1.49 | -4.4% | Miss |
| 08 May 2024 16:00 | -1.46 | -1.43 | +2.4% | Beat |
| 21 Feb 2024 07:00 | 0.05 | 1.10 | +2,212.9% | Beat |
| 06 Nov 2023 16:00 | -1.95 | -1.41 | +27.7% | Beat |
| 07 Aug 2023 16:00 | -2.10 | -0.98 | +53.4% | Beat |
| 08 May 2023 16:00 | -1.64 | -0.67 | +59.1% | Beat |
| 21 Feb 2023 16:00 | -2.27 | -1.41 | +37.9% | Beat |
| 01 Nov 2022 16:00 | -2.24 | -2.24 | -0.1% | In line |
| 08 Aug 2022 08:00 | -2.21 | -2.40 | -8.8% | Miss |
| 09 May 2022 16:00 | -1.97 | -2.32 | -17.6% | Miss |
| 15 Feb 2022 16:00 | -1.78 | -1.84 | -3.4% | Miss |
| 03 Nov 2021 16:00 | -1.76 | -1.67 | +5.3% | Beat |
| 29 Jul 2021 16:00 | 3.12 | 9.44 | +202.6% | Beat |
| 27 Apr 2021 16:00 | -1.47 | -1.51 | -2.5% | Miss |
| 16 Feb 2021 16:00 | -1.28 | -1.52 | -19.2% | Miss |
| 28 Oct 2020 08:00 | -1.19 | -1.32 | -11.2% | Miss |
| 27 Jul 2020 16:00 | -0.99 | -1.30 | -31.6% | Miss |
| 28 Apr 2020 16:00 | -1.04 | -1.15 | -10.3% | Miss |
| 12 Feb 2020 16:00 | 0.05 | 0.51 | +839.6% | Beat |
| 28 Oct 2019 07:00 | 1.79 | 2.40 | +33.8% | Beat |
| 29 Jul 2019 16:00 | -0.90 | -1.01 | -12.8% | Miss |
| 29 Apr 2019 16:00 | -0.90 | -0.93 | -3.5% | Miss |
| 25 Feb 2019 08:00 | -0.78 | -0.92 | -18.5% | Miss |
| 07 Nov 2018 16:00 | -0.74 | -1.07 | -44.2% | Miss |
| 07 Aug 2018 16:00 | -0.64 | -0.82 | -28.0% | Miss |
| 08 May 2018 07:00 | -0.67 | -0.62 | +7.5% | Beat |
| 08 Mar 2018 16:00 | -0.67 | — | +100.0% | — |
| 08 Nov 2017 16:00 | -0.60 | -0.62 | -3.2% | Miss |
| 10 Aug 2017 16:00 | -0.62 | -0.56 | +9.3% | Beat |
| 11 May 2017 08:00 | -0.65 | -0.54 | +16.7% | Beat |
| 10 Mar 2017 16:00 | -0.49 | -0.62 | -27.7% | Miss |
| 22 Nov 2016 06:00 | -0.38 | -0.37 | +2.9% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | -100.0% | -581.6M | — | -6.47 | -49.1% | -370.9M |
| 2024 | 35M | -90.5% | -366.3M | -1,046.4% | -4.34 | -123.7% | -144.7M |
| 2023 | 370M | +84,762.4% | -153.6M | -41.5% | -1.94 | +76.8% | -272.3M |
| 2022 | 436K | — | -650.2M | -149,122.7% | -8.36 | — | -532.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 45.09 | 45.09 | 42.38 | 42.62 | -6.84% | 2,485,000 | |
| 11 Nov 2026 | 45.97 | 46.31 | 44.49 | 45.75 | +1.33% | 2,676,800 | |
| 10 Nov 2026 | 49.02 | 49.29 | 44.99 | 45.15 | -9.77% | 4,007,600 | |
| 09 Nov 2026 | 50.57 | 51.52 | 48.69 | 50.04 | -0.06% | 1,059,000 | |
| 06 Nov 2026 | 48.98 | 50.27 | 48.41 | 50.07 | +3.11% | 1,234,300 | |
| 05 Nov 2026 | 51.01 | 51.21 | 47.76 | 48.56 | -6.21% | 2,144,600 | |
| 04 Nov 2026 | 51.48 | 52.50 | 50.19 | 51.78 | +3.57% | 1,392,400 | |
| 03 Nov 2026 | 50.26 | 51.86 | 49.62 | 49.99 | 0.00% | 1,288,700 | |
| 02 Nov 2026 | 51.90 | 52.12 | 49.70 | 49.99 | -2.78% | 1,020,000 | |
| 30 Oct 2026 | 53.27 | 54.10 | 50.60 | 51.42 | -5.23% | 1,166,800 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Crispr Therapeutics: More Patients, Same Losses (opens in a new tab) SeekingAlpha · 12 Nov 2026 08:55
- CRISPR Therapeutics AG (CRSP) Presents at AHA Scientific Sessions 2026 - Slideshow (opens in a new tab) SeekingAlpha · 11 Nov 2026 18:14
- Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment (opens in a new tab) SeekingAlpha · 10 Nov 2026 14:54
- CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy (opens in a new tab) Benzinga · 10 Nov 2026 14:48
- CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (opens in a new tab) 10 Nov 2026 13:30
- CRISPR Therapeutics: I Love The Medical Breakthroughs, I Don't Love The Stock - Strong Sell (opens in a new tab) SeekingAlpha · 09 Nov 2026 16:47
- CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026 (opens in a new tab) 09 Nov 2026 14:16
- CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases (opens in a new tab) Benzinga · 09 Nov 2026 10:17
- Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response (opens in a new tab) Benzinga · 09 Nov 2026 04:11
- CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases (opens in a new tab) 08 Nov 2026 15:30
- CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (opens in a new tab) Zacks · 06 Nov 2026 13:00
- Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90 (opens in a new tab) Benzinga · 04 Nov 2026 17:11
- CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (opens in a new tab) 04 Nov 2026 14:01
- Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70 (opens in a new tab) Benzinga · 04 Nov 2026 11:50
- Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead (opens in a new tab) Investor's Business Daily · 03 Nov 2026 21:31
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 45.75 USD
- Market cap
- 4.1B
- Exchange
- NasdaqGM
- Country
- Switzerland
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow CRSP and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.